Effect of 18 Months of Teriparatide Therapy on Bone Microarchitecture and Bone Volume in Postmenopausal Women with Osteoporosis

18个月特立帕肽治疗对绝经后骨质疏松症女性骨微结构和骨量的影响

• 批准号: 176104
• 负责人: Cheung Angela M
• 金额: $ 5.65万
• 依托单位: University Health Network (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2008
• 资助国家: 加拿大
• 起止时间: 2008-09-01 至 2009-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=176104&lang=en
• 关键词: High Resolution Peripheral Quantitative Computer Tomography; Open Label Before And After Study; Postmenopausal Women With Osteoporosis; Teriparatide

Clinical trials have shown that teriparatide, a bone formation drug, increases bone mineral density (BMD) at the lumbar spine and total hip, but decreases BMD at the forearm after 20 months of therapy. It is unclear whether this decrease in BMD at the fo

临床试验表明，特立哌酮，一种骨形成药物，增加腰椎和全髋关节的骨矿物质密度（BMD），但在治疗20个月后降低前臂的BMD。 目前还不清楚这种骨密度的降低是否与骨密度的增加有关。